Teclistamab (Tecvayli) is an off-the-shelf first-in-class bispecific monoclonal antibody shown in the MajesTEC-1 trial to ...

94% of Advanced Practice Providers (APPs) believe more educational resources about the rare blood cancer multiple myeloma could help improve the patient experience HORSHAM, Pa., Sept. 26, 2023 ...

The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus daratumumab (Darzalex, Johnson & Johnson/Janssen) reduced the risk for ...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the launch of That’s My Word™ to raise awareness of and help to drive better health outcomes for multiple myeloma among ...

EXTON, Pa., Oct. 30, 2019 /PRNewswire/ -- In late June 2019, Darzalex, in combination with lenalidomide and dexamethasone (DRd), was approved for the first-line treatment of patients with newly ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...

Johnson & Johnson has seen response rates as high as 97% in multiple myeloma before but this time, it’s not for Carvykti, which is making headlines of its own at the American Society of Clinical ...

That's My Word™ campaign issues national call to action for earlier diagnosis and treatment to address the disproportionate impact of multiple myeloma among at-risk communities HORSHAM, Pa., March 2, ...

Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9203951-janssen-make-it-happen-campaign-supports-apps-caring ...